Biopharmaceutical News and Research

RSS

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

FDA takes first steps in bringing clarity to emerging area of individualized drug development

Advances in scientific knowledge and drug development technology have provided an opportunity for new approaches to drug development, including the development of drugs for the treatment of rare diseases.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody.

18 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.

15 Dec 2020

Researchers develop new technology for efficient production of monoclonal antibodies

Proteins in biopharmaceutical productions are usually separated and purificated through the expensive chromatography technique. European researchers are developing an innovative membrane crystallization technology to overcome the issue and make the production of monoclonal antibodies more efficient.

15 Dec 2020

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.

14 Dec 2020

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth

As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade.

From Takeda 10 Dec 2020

FUJIFILM Irvine Scientific launches Sterile Express Media Service

FUJIFILM Irvine Scientific, Inc., today announced the launch of Sterile Express Media Service (SEMS), for small-scale, rapid production of non-GMP media tested for sterility.

4 Dec 2020

Nanomedicine's giant step into the fight against the COVID-19

A recent editorial in Nature Nanotechnology discusses the enormous feat of scientific innovation, with messenger RNA (mRNA)-based vaccines developed to deliver the gene sequence of specific SARS-CoV-2 viral proteins into host cells using nanotechnology platforms.

1 Dec 2020

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis

Marinomed Biotech AG, a globally operating biopharmaceutical company, is pleased to announce today that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID).

30 Nov 2020

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.

25 Nov 2020

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer is poised for clinical testing to begin in December.

25 Nov 2020

Marinomed to initiate clinical trial with Carragelose for preventing COVID19 in frontline healthcare staff

Marinomed Biotech AG, a globally operating biopharmaceutical company, announced today plans to initiate a Phase IV clinical trial with Carragelose (iota-carrageenan).

23 Nov 2020

Oxford University and AstraZeneca release their COVID-19 vaccine results

AstraZeneca and the University of Oxford have just released their results from its interim analysis of AZD1222, a vaccine being trialed to prevent COVID-19.

From AstraZeneca 23 Nov 2020

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Now, Sinovac Biotech's candidate vaccine, CoronaVac, has been found to induce an immune response in healthy adults aged 18–59 years, 28 days post-vaccination. However, the level of antibodies generated was lower than in people who had recovered from the illness.

19 Nov 2020

Promising new compounds to potentially treat novel coronaviruses identified

Researchers at the University of Maryland School of Medicine and School of Pharmacy have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19.

15 Nov 2020

Biopharmaceutical News and Research

CytoDel successfully delivers neuronal antibody in animal models of botulism

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

FDA takes first steps in bringing clarity to emerging area of individualized drug development

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

RedHill Biopharma announces promising preliminary results from opaganib study

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

Researchers develop new technology for efficient production of monoclonal antibodies

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth

FUJIFILM Irvine Scientific launches Sterile Express Media Service

Nanomedicine's giant step into the fight against the COVID-19

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis

Novel CAR T-cell therapy shows promising early results in children with neuroblastoma

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

Marinomed to initiate clinical trial with Carragelose for preventing COVID19 in frontline healthcare staff

Oxford University and AstraZeneca release their COVID-19 vaccine results

Sinovac Biotech's COVID-19 vaccine candidate triggers immune response

Promising new compounds to potentially treat novel coronaviruses identified

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News